Assessment of diagnostic gain with hexaminolevulinate (HAL) in the setting of newly diagnosed non-muscle-invasive bladder cancer with positive results on urine cytology

Urologic Oncology: Seminars and Original Investigations

Volumn 32, Issue 8, 2014, Pages 1135-1140

  Neuzillet, Yann ^a,b   Methorst, Charlotte ^a   Schneider, Marc ^c   Lebret, Thierry ^a,b   Rouanne, Mathieu ^a,b   Radulescu, Camelia ^a   Molinie, Vincent ^d   Dreyfus, Jean François ^a   Pelcat, Veronique ^a   Botto, Henry ^a  

^a FOCH HOSPITAL   (France)

^b LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^c Pasteur Hospital   (France)

^d CENTRE HOSPITALIER UNIVERSITAIRE DE FORT DE FRANCE   (France)

Author keywords

Hexaminolevulinate; High grade cytology; Non muscle invasive bladder cancer; Photodynamic diagnosis; Second TURB; Transurethral resection of bladder

Indexed keywords

AMINOLEVULINIC ACID HEXYL ESTER; 5-AMINOLEVULINIC ACID HEXYL ESTER; AMINOLEVULINIC ACID; PHOTOSENSITIZING AGENT;

AGED; ARTICLE; BLADDER MUSCLE; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER SURGERY; CONTROLLED STUDY; CYSTECTOMY; CYSTOSCOPY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON MUSCLE INVASIVE BLADDER CANCER; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; URINE CYTOLOGY; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; MULTICENTER STUDY; PATHOLOGY; PHOTOCHEMOTHERAPY; PROCEDURES; URINARY BLADDER NEOPLASMS; URINE; UROLOGIC SURGERY;

AGED; AMINOLEVULINIC ACID; CYSTOSCOPY; FEMALE; HUMANS; MALE; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PROSPECTIVE STUDIES; URINARY BLADDER NEOPLASMS; UROLOGIC SURGICAL PROCEDURES;

EID: 84925945037     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2014.04.005     Document Type: Article

References (29)

1. Babjuk M., Oosterlinck W., Sylvester R., et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol 2011, 59:997-1008.
2. Kausch I., Sommerauer M., Montorsi F., et al. Photodynamic diagnosis in non-muscle-invasive bladder cancer: a systematic review and cumulative analysis of prospective studies. Eur Urol 2010, 57:595-606.
3. Sylvester R.J., van der Meijden A.P., Oosterlinck W., et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006, 49:466-475.
4. Burger M., Grossman H.B., Droller M., et al. Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data. Eur Urol 2013, 64:846-854.
5. Filbeck T., Pichlmeier U., Knuechel R., Wieland W.F., Roessler W. Do patients profit from 5-aminolevulinic acid-induced fluorescence diagnosis in transurethral resection of bladder carcinoma?. Urology 2002, 60:1025-1028.
6. Fradet Y., Grossman H.B., Gomella L., et al. A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study. J Urol 2007, 178:68-73.
7. Schmidbauer J., Witjes F., Schmeller N., Donat R., Susani M., Marberger M., et al. Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy. J Urol 2004, 171:135-138.
8. Jocham D., Witjes F., Wagner S., et al. Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: a prospective, phase III multicenter study. J Urol 2005, 174:862-866.
9. Drăgoescu O., Tomescu P., Pănuş A., et al. Photodynamic diagnosis of non-muscle invasive bladder cancer using hexaminolevulinic acid. Rom J Morphol Embryol 2011, 52:123-127.
10. Lapini A., Minervini A., Masala A., et al. A comparison of hexaminolevulinate (Hexvix®) fluorescence cystoscopy and white-light cystoscopy for detection of bladder cancer: results of the HeRo observational study. Surg Endosc 2012, 26:3634-3641.
11. Loidl W., Schmidbauer J., Susani M., Marberger M. Flexible cystoscopy assisted by hexaminolevulinate induced fluorescence: a new approach for bladder cancer detection and surveillance?. Eur Urol 2005, 47:323-326.
12. Stenzl A., Burger M., Fradet Y., et al. Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer. J Urol 2010, 184:1907-1913.
13. Karaolides T., Skolarikos A., Bourdoumis A., et al. Hexaminolevulinate-induced fluorescence versus white light during transurethral resection of noninvasive bladder tumor: does it reduce recurrences?. Urology 2012, 80:354-359.
14. Kriegmair M., Zaak D., Rothenberger K.H., et al. Transurethral resection for bladder cancer using 5-aminolevulinic acid induced fluorescence endoscopy versus white light endoscopy. J Urol 2002, 168:475-478.
15. Geavlete B., Jecu M., Multescu R., Georgescu D., Geavlete P. HAL blue-light cystoscopy in high-risk nonmuscle-invasive bladder cancer-re-TURBT recurrence rates in a prospective, randomized study. Urology 2010, 76:664-669.
16. Otto W., Burger M., Fritsche H.M., et al. Photodynamic diagnosis for superficial bladder cancer: do all risk-groups profit equally from oncological and economic long-term results?. Clin Med Oncol 2009, 3:53-58.
17. Hermann G.G., Mogensen K., Carlsson S., Marcussen N., Duun S. Fluorescence-guided transurethral resection of bladder tumours reduces bladder tumour recurrence due to less residual tumour tissue in Ta/T1 patients: a randomized two-centre study. BJU Int 2011, 108:E297-E303.
18. Divrik R.T., Sahin A.F., Yildirim U., Altok M., Zorlu F. Impact of routine second transurethral resection on the long-term outcome of patients with newly diagnosed pT1 urothelial carcinoma with respect to recurrence, progression rate, and disease-specific survival: a prospective randomised clinical trial. Eur Urol 2010, 58:185-190.
19. Lokeshwar V.B., Habuchi T., Grossman H.B., et al. Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers. Urology 2005, 66:35-63.
20. Epstein J.I., Amin M.B., Reuter V.R., Mostofi F.K. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol 1998, 22:1435-1448.
21. Geavlete B., Multescu R., Georgescu D., Jecu M., Stanescu F., Geavlete P. Treatment changes and long-term recurrence rates after hexaminolevulinate (HAL) fluorescence cystoscopy: does it really make a difference in patients with non-muscle-invasive bladder cancer (NMIBC)?. BJU Int 2012, 109:549-556.
22. Grossman H.B., Stenzl A., Fradet Y., et al. Long-term decrease in bladder cancer recurrence with hexaminolevulinate enabled fluorescence cystoscopy. J Urol 2012, 188:58-62.
23. Witjes J.A. Bladder carcinoma in situ in 2003: state of the art. Eur Urol 2004, 45:142-146.
24. Sylvester R.J., van der Meijden A., Witjes J.A., et al. High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder. Urology 2005, 66:90-107.
25. Gan C., Patel A., Fowler S., Catto J., Rosario D., O'Brien T. Snapshot of transurethral resection of bladder tumours in the United Kingdom Audit (STUKA). BJU Int 2013, 112:930-935.
26. Rouprêt M., Yates D.R., Varinot J., et al. The presence of detrusor muscle in the pathological specimen after transurethral resection of primary pT1 bladder tumors and its relationship to operator experience. Can J Urol 2012, 19:6459-6464.
27. Mariappan P., Finney S.M., Head E., et al. Good quality white-light transurethral resection of bladder tumours (GQ-WLTURBT) with experienced surgeons performing complete resections and obtaining detrusor muscle reduces early recurrence in new non-muscle-invasive bladder cancer: validation across time and place and recommendation for benchmarking. BJU Int 2012, 109:1666-1673.
28. Burger M., Zaak D., Stief C.G., et al. Photodynamic diagnostics and noninvasive bladder cancer: is it cost-effective in long-term application? A Germany-based cost analysis. Eur Urol 2007, 52:142-147.
29. Strittmatter F., Buchner A., Karl A., et al. Individual learning curve reduces the clinical value of urinary cytology. Clin Genitourin Cancer 2011, 9:22-26.